Welcome Guest | Register / Login

Saudi Arabia Pharmaceutical Market Opportunity Analysis

Table of Contents

1. Saudi Arabia Pharmaceutical Market Overview
1.1 Current Market Overview
1.2 Drug Pricing System
1.3 Disease Prevalence

2. Pharmaceutical Market by Segment
2.1 Branded Drugs
2.2 Generic drugs
2.3 OTC

3. Favourable Market Dynamics
3.1 Largest Market in Middle East
3.2 Promotion of Domestic Pharmaceutical Industry
3.3 Well Established Regulatory Framework
3.4 Demand for OTC & Generics Drugs
3.5 Import Dependent Market
3.6 Challenges to be Resolved
3.7 Future Growth Avenues

4. Regulatory & Policy Framework
4.1 Drug Approval Process (Generics, Biologicals, Radipharmaceuticals &New Chemical Entity)
4.2 Monoclonal Antibodies and Related Products Quality Guideline
4.3 Law of Pharmaceutical Establishments and Preparations
4.4 Guidelines on Biosimilars
4.4.1 Insulin
4.4.2 Interferons
4.4.3 Erythropoietin
4.4.4 Granulocyte-Colony Stimulating Factor
4.4.5 Human Growth Hormone

5. Competitive Landscape
5.1 SPIMACO
5.2 Tabuk Pharmaceuticals
5.3 Jamjoom Pharma
5.4 Julphar (Gulf Pharmaceutical Industries)
5.5 GSK
5.6 Pfizer
5.7 Novartis
5.8 Astra

List of Tables

Table 1-1: Pricing History and Legal Background in Saudi Arabia
Table 1-2: Drug Pricing for Generics
Table 1-3: Drug Pricing for Fixed Combinations

List of Figures

Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2012-2018
Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2012-2018
Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2012 & 2018
Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market
Figure 1-5: Components of Drug Pricing System in Saudi Arabia
Figure 1-6: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030
Figure 1-7: Leading Causes of Death in Saudi Arabia, 2011
Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2012-2018
Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2012-2018
Figure 2-3: Saudi Arabian OTC Drug Market(US$ Billion), 2012-2018
Figure 3-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2012
Figure 3-2: Government Expenditure on Health as a % of Total Health Expenditure, 2011
Figure 3-3: Expenditure on Health as a % of Total Government Expenditure, 2011
Figure 4-1: Saudi Arabia Drug Approval Process

Why http://www.marketreportsonline.com/
Published By :Kuick Research
Price
Live Chat
Live Chat by Comm100